---
id: rotaviruses_302
category: organisms
tags: [rotavirus, gastroenteritis, RotaTeq, Rotarix, vaccination, intussusception, pediatrics]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Rotaviruses

**Q:** What are the rotavirus vaccine types, schedules, efficacy, and intussusception risk?

**A:**

**Clinical Disease:**
- **Leading cause** of severe diarrhea/dehydration in infants/young children worldwide
- Transmission: fecal-oral route
- Clinical: watery diarrhea, vomiting, fever, dehydration

**Vaccines:**

| Vaccine | Type | Doses | Schedule | Serotype Coverage |
|---------|------|-------|----------|-------------------|
| **RotaTeq (RV5)** | Live, oral pentavalent | **3 doses** | **2, 4, 6 months** (ages 6-12 weeks to 32 weeks) | G1, G2, G3, G4, G9 |
| **Rotarix (RV1)** | Live, oral monovalent | **2 doses** | **2, 4 months** (ages 6 weeks to 24 weeks) | G1 + non-G1 types (G3, G4, G9) |

**Timing Requirements (CRITICAL):**
- **First dose**: Before **15 weeks of age**
- **Complete series**: Before **8 months of age**
- **Maximum age for last dose**:
  - RotaTeq: **32 weeks**
  - Rotarix: **24 weeks 6 days**

**Vaccine Efficacy:**
- **90% protection** against severe rotavirus disease
- **70% protection** against any rotavirus disease

**Intussusception Risk:**

| Feature | Details |
|---------|---------|
| **Incidence** | **1-7 cases per 100,000 infants vaccinated** (most studies: ≤2/100,000) |
| **Timing** | **Within 7 days** after first or second dose (clustering in first 7 days) |
| **Overall risk** | **1 in 20,000 to 1 in 100,000** US infants |
| **Contraindication** | History of intussusception |

**Key Points:**
- Vaccine benefits far outweigh intussusception risk
- Cannot start vaccine series after 15 weeks (increased intussusception risk)
- Live virus → avoid in severe immunocompromised infants

**Mnemonic - "2-4-6 for RotaTeq Three"**: RotaTeq given at 2, 4, 6 months (3 doses)

**Pearl:** Rotavirus vaccine has strict age limits (first dose <15 weeks, series complete <8 months) to minimize intussusception risk. Benefits overwhelmingly outweigh small intussusception risk (1-2/100,000).

**Media:**

**Sources:** [CDC Rotavirus Vaccination 2024], [CDC Pink Book Rotavirus Chapter], [NEJM Intussusception Risk 2014], [RotaTeq/Rotarix Prescribing Information]
